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INTRODUCTION 
Adverse event is defined as any untoward medical 
occurrence that may present during treatment 
with a pharmaceutical product but which does not 
necessarily have a causal relationship with 
treatment.1  When a causal relationship is 
established between suspected drug and adverse 
event, it becomes adverse drug reaction (ADR) or 
adverse drug effect.2  ADRs are a major problem 
worldwide. Serious adverse events include events 
which are life-threatening or lead to death, 
hospitalization (initial or prolonged), disability - 
significant, persistent, or permanent change, 
impairment, damage or disruption in the patient's 
body function/structure, physical activities or 
quality of life, congenital anomaly, require 
intervention to prevent permanent impairment or 
damage.3 
 
Even in developed countries like US, where drugs 
are used cautiously, the mean number of SAEs per 
patient was 0.021.0, SAEs per patient per month 
was 0.0031.0, SAEs per site was 0.30.7, and SAEs  
 
per site per month was 0.040.07.4  In India, due to 
malpractice by unqualified practitioners and 
unsupervised usage of drugs, serious ADR 
incidence is likely to be high and lead to mortality 
and high managing burden for society.5 As ADRs 
result in significant morbidity, extended hospital 
stay, increased health expenditure and mortality, 
so drugs must be prescribed rationally and 
constant monitoring of ADRs especially causing 
serious ADRs is mandatory.  
 
 Every medicine is tested on a relatively small 
number of the participants, in highly selected 
patients in pre-marketing trials excluding 
pregnant females, lactating women, children and 
elderly, those with complicated medical condition 
and on multiple drug combinations for only short-
term period.6-8 Therefore, adverse reactions 
having frequency less than 0.5 to 1% are missed 
and adverse reactions that appear within the 
predetermined duration of trial are reported.9   
Delayed reactions and ADRs occurring with  
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chronic use are missed in pre-marketing trials.10 As    
the drug is marketed, it is administered to several 
thousand patients with multiple medical 
problems and on multiple drug therapies in 
different age groups.11 Therefore, ADR monitoring 
should be started along with administration of 
drug and continued throughout life of the drug, so 
that we can understand safety profile of drug and 
compare it with benefits provided by the drug.12   
   
After the Thalidomide disaster of 1962, 
Pharmacovigilance programs were set up in many 
countries like UK, Australia, New Zealand, Canada 
and Sweden in 1964-65 to monitor adverse events 
with special focus on finding serious adverse 
events.13 Central Drugs Standard Control 
Organization (CDSCO) has initiated a well 
structured and highly participative 
Pharmacovigilance Programme of India (PvPI). In 
spite of all factors, pharmacovigilance has not 
picked up well in India and the reporting is still 
poor. India rates below 1% in pharmacovigilance 
as against the world rate of 5%.14  
 
In India, DCGI has taken an initiative by 
establishing Adverse event reporting center in 
Medical college and creating awareness among 
patients and physicians to report adverse events to 
these centers or by mobile application (ADR 
monitoring), with focus on finding of Serious 
adverse events.15 Serious adverse event are to be 
reported within seven days in post-marketing 
period and within 14 days by sponsor in clinical 
trial.16  Data about serious ADRs is deficient so this 
study was planned as a preliminary initiative to 
contribute to PvPI. 
 
MATERIAL AND METHODS   
Source of Data   
This prospective observational study was carried 
out on patients admitted in Medical College of 
North India for a duration of six months i.e. from 
July, 2014 to January, 2015 after taking clearance 
from the institutional ethical committee. A 
written informed consent was taken from the 
patients for participation in the study after 
screening for serious adverse event. All patients 
were interviewed and their data was recorded in a 
performa. Patient of any age and gender having 
serious adverse event were included in the study. 
All reactions were reviewed and causality 
assessment was done according to the WHO UMC 
causality assessment scale to label adverse event 
as adverse drug reaction. History of the disease 
along with the drug history, duration of drug 
intake and ADR associated with drug therapy was 
recorded. The performa filled for the adverse 
events experienced by the patients for ADR 
monitoring was designed on the basis of WHO 
guidelines and the form also included details like 
age, gender, other demographic details, past 
medical history, present drug treatment, 
description of adverse event, its assessment and 
treatment for the drug reaction. Regular follow up 
of the patient was done for a minimum of seven 
days to a maximum of 14 days to assess the 
response of treatment. The scoring of adverse 
events was done according to WHO UMC 
Casualty assessment scale.17 No re-challenge with 
the drug was performed to confirm the 
relationship.  
  
Statistical analysis 
The data collected was recorded in a performa and 
was analysed using descriptive statistics.   
 
OBSERVATIONS  
The 2933 patients with adverse events were 
screened over a period of six months in Medical 
College of North India, out of which 66 serious 
ADRs were reported in 60 patients. 
 
The most common drug leading to Serious 
Adverse Drug Reaction was Phenytoin (13%) 
followed by Paclitaxel (10%) as shown in Table 1. 
The most common ADR noted was Rash leading 
to hospitalization (31.18%) and Steven Johnson 
Syndrome (31.18%), followed by Fever (16.60%), 
Anaphylactic Reactions (5%), DRESS (5%) and 
Toxic epidermal necrolysis (5%) as shown in Table 
2. Patients suffering from serious ADRs due to 
phenytoin and paclitaxel are shown in figure 1 and 
2 respectively. 
 
ADR incidence was found to be 1.11 per patient. 
The average number of drugs prescribed was 1.64 
per patient. Incidence of Serious ADRs was 
0.04%.Mortality was reported in 3 patients. Two 
patients died due to hypersensitivity reaction to 
contrast media while 1 patient having chronic liver 
disease died due to hypersensitivity reaction to 
flex albumin while 33 patients were hospitalized 
and in 24 patients stay was prolonged due to ADR.  
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A difference in adverse drug reactions according 
to age was also seen. Mean age of patients was 
46.90 years. The adverse drug reactions were 
reported more in females i.e. 33(55.69) as 
compared to the males-i.e. 27(45.30) as shown in 
Table 3. 
 
Demographic profile 
There was difference in adverse drug reactions 
according to demographic profile. Urban patients 
constituted 40 (66.31%) of adverse drug reactions 
and rural patients constituted 20(32.69%).  
 
Causality assessment  
A causal relationship between the drug and the 
reaction was assessed depending upon the lag 
period between the start of the drug and 
appearance of the reaction, response to de-
challenge, laboratory tests and the data available 
regarding the drug using the WHO UMC causality 
assessment scale. Dechallenge (discontinuation of 
the suspected drug) was done in 22 %cases, 
whereas in 78 % of the cases initial drug therapy 
was continued. Causality assessment was done 
according to WHO UMC causality assessment in 
figure 3. All data of serious ADRs was reported to 
PvPI in Vigibase through vigiflow software in 
regional ADR monitoring center. 
 
DISCUSSION  
A wide range of serious adverse drug reactions are 
caused by various drugs. The present study was 
conducted in patients admitted in a Medical 
College and Hospital of North India. The serious 
ADRs were recorded over a period of six months. 
The frequency and distribution of serious adverse 
drug reactions and drugs implicated in these 
reactions were studied.  
 
A total of 66 serious ADRs were reported during 
this duration in 60 patients (27 males, 33 females). 
Mean age of patients was 46.90 years. ADR 
incidence was found to be 1.11 per patient. The 
average number of drugs prescribed was 1.64 per 
patient. The most common drug leading to 
Serious Adverse Drug Reaction was Phenytoin 
(13%) followed by Paclitaxel (10%). The most 
common ADR noted was Rash leading to 
hospitalization (31.18%) and Steven Johnson 
Syndrome (31.18%), followed by Fever (16.60%), 
Anaphylactic Reactions (5%), DRESS (5%) and 
Toxic epidermal necrolysis (5%). 
 Similar pattern of adverse reactions were 
observed in different studies. These studies 
included on average: 502311 patients, 301.5 clinical 
sites per study as well as 2.20.6 treatment arms 
lasting 7.79.6 months. There were 8616 (42.9%) 
males and 9298 (46.3%) females; 2017 (10.0%) 
African Americans, 15,248 (75.9%) Caucasians, and 
1436 (7.1%) other races, as well as 18,724 
monotherapy (93.2%) and 1379 (6.8%) adjunctive 
therapy patients. The average age was 63.41.8 
years. There were 7 studies missing at least some 
demographic data. Of the included studies, 35 
evaluated prostaglandins, 34 beta-blockers, 14 
carbonic anhydrase inhibitors (CAI), and 7 alpha-
agonists as well as studies evaluating 
prostaglandin (n=1), alpha-agonist (n=2 ), and CAI 
(n=2) based fixed combinations. 449 (2.3%) total 
SAEs were reported in the reviewed articles. Of 
these, 20 (4.5%) were deaths, 41 (9.1%) 
hospitalizations/ surgeries, and 377 (84.0%) with 
type not reported. Also, 11 (2.5%) SAEs were 
related to the study medicine by the investigator. 
The average number of SAEs per study was 11.23.1. 
In addition, there were 1.51.0 SAEs per month per 
study. The mean number of SAEs per patient was 
0.021.0, SAEs per patient per month was 0.0031.0, 
SAEs per site was 0.30.7, and SAEs per site per 
month was 0.040.07. 
 
Separate multilinear regression analyses for 
patient and study characteristics associated with 
SAEs demonstrated that risk factors were 
advanced age (P0.0001) and increased study 
length (P0.0001).In contrast, the risk for higher 
incidence of SAE potentially may be related to 
larger sample size, longer study length, and older 
age. However, any favorable effect of altering 
study design to potentially reduce SAE incidence 
should be carefully assessed by the impact on the 
study conclusions, especially patient safety, and 
the regulatory labeling.18     
 
 As any other study, our study too has few 
limitations. We studied only the patients reported 
for adverse events and study was limited for six 
months. We, however, feel that the duration of the 
study and sample size was adequate for the given 
period of study. 
 
CONCLUSIONS  
Serious ADR monitoring of drugs is important as 
it clarifies the safety of available drugs. ADR 
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monitoring and reporting activity is still in 
establishment phase in India.   
 
The present study was conducted with an aim to 
determine frequency and distribution of serious 
adverse events in a Tertiary care hospital in North 
India for a duration of six months. Data regarding 
the patient demographics and ADRs was collected 
by patient interviews and entered in individual 
proforma. Causality was assessed by both WHO 
causality assessment scale. Most common serious 
ADRs reported were Rash (27.27%) and Steven 
Johnson Syndrome (27.27%). Incidence of Serious 
ADRs was 0.04%. All the ADRs were managed as 
per standard protocol. Mortality was reported in 3 
patients. It can be concluded that high risk drugs 
are not entirely safe and there is an urgent need 
for monitoring these drugs. This can be done by 
post marketing surveillance at large number of 
centers over a long period of time.   
 
However these results need to be verified in multi-
centric studies as sample size for some of them 
were small and hence cannot be extrapolated to 
large population. Since all the serious adverse 
effects of the drugs cannot be prevented, it is 
necessary to create awareness about patterns of 
adverse reactions and the common drugs 
implicated in these reactions. Patients should be 
aware of these ADRs so that these can be taken 
care of at an early stage. We should monitor safety 
of high risk drugs monthly by starting task 
specifically oriented towards monitoring serious 
adverse events in patients taking these drugs. This 
will enhance the safety of high risk drugs.  
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DRUG Frequency of ADRs 
PHENYTOIN 10 
PACLITAXEL 7 
RIFAMPICIN 6 
PYRAZINAMIDE 5 
ETHAMBUTOL 5 
LEVITERACETAM 4 
ISONIAZID 4 
CLONAZEPAM 3 
QUETIAPINE 3 
CYTOCARBOPLATIN 3 
PHENOBARBITONE 2 
AZITROMYCIN 2 
CEFUROXIME 2 
CLOXACILIN 2 
PROGESTERONE 2 
ISOXPURINE 2 
CYCLOPHOSPHAMIDE 2 
DEXAMETHASONE 2 
VALPROATE 2 
CONTRAST MEDIA 2 
FLUROURACIL 1 
GEMCITABINE 1 
STREPTOMYCIN 1 
METHOTREXATE 1 
CYTARABINE 1 
AMIKACINE 1 
DICLOFENAC 1 
PARACETAMOL 1 
INDOMETHACIN 1 
SULFASALAZINE 1 
ALLOPURINOL 1 
CARBAMEZAPINE 1 
IVIG 1 
LEGENDS 
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PROBIOTICS 1 
ALBUMIN 1 
ASPIRIN 1 
HYDROCLORTHIAZIDE 1 
ADR DRUG CATEGORY DRUG  FREQUENCY 
  
  
  SJS 
  
  
  
  
  
  
  
  
  
  
  
  
ANTICONVULSANT  
  
  
PHENYTION  3 
PHENOBARBITONE  1 
LEVETRICITAM  1 
ANTITUBERCULAR  
  
  
  
RIFAMPICIN  2 
PYROZINAMIDE  2 
ETHAMBUTOL  2 
ISONIZID  1 
ANTI BIOTICS  
  
  
AZITHROMYCIN  1 
CEFOPODOXIME  1 
CLOXACILLIN  1 
ANTI PSYCHOTICS  QUETIAPINE  1 
ANTI ANXIETY  CLONAZEPAM  1 
HORMONE  PROGESTRONE  1 
VASODILATOR  ISOXPURINE  1 
   TOTAL  21 
RASH  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
ANTICONVULSANT  
  
  
PHENYTION  3 
LEVETRICITAM  1 
PHENOBARBITONE  1 
ANTITUBERCULAR  
  
  
  
RIFAMPICIN  2 
PYROZINAMIDE  2 
ETHAMBUTOL  2 
ISONIZID  1 
ANTI BIOTICS  
  
  
AZITHROMYCIN  1 
CEFOPODOXIME  1 
CLOXACILLIN  1 
ANTI PSYCHOTICS  QUETIAPINE  1 
ANTI ANXIETY  CLONAZEPAM  1 
HORMONE  PROGESTRONE  1 
VASODILATOR  ISOXSUPRINE  1 
   TOTAL 21 
       
  FEVER 
  
  
  
ANTICANCER  
  
  
  
PACLITAXEL  2 
CYTOCARBOPLATIN  2 
CYCLOPHOSPHAMIDE  1 
FLUROURACIL  1 
GEMCITABINE  1 
 CORTICOSTEROID DEXAMETHASONE  2 
   TOTAL 9 
Table 1. Frequency of ADRs caused by drugs 
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TEN ANTICONVULSANTS LEVITERACETAM 2 
VALPROATE 2 
 PHENYTOIN 1 
ANTIBIOTICS STREPTOMYCIN 1 
ANTI PSYCHOTIC QUETIAPINE 1 
ANTI ANXIENTY CLONAZEPAM 1 
 TOTAL 8 
DYSPNEA ANTICANCER PACLITAXEL 2 
CYCLOPHOSPHAMIDE 1 
CYTOCARBOPLATIN 1 
METHOTREXATE 1 
CYTARABINE 1 
ANTI BIOTICS AMIKACIN 1 
 TOTAL 7 
HEPATITIS    
ANTI CONVULSANTS PHENYTION 1 
ANTI TUBERCULAR RIFAMPICIN 2 
ISONIZID 2 
PYROZINAMIDE 1 
ETHAMBUTOL 1 
  TOTAL 7 
DRESS ANALGESICS DICLOFENAC 1 
PARACETAMOL 1 
INDOMETHACIN 1 
ANTI BIOTICS SULFASALAZINE 1 
XANTHINE OXIDASE 
INHIBTOR 
ALLOPURINOL 1 
ANTICONVULSANT CARBAMEZAPINE 1 
  TOTAL 6 
ANAPHYLACTIC 
REACTION 
   
  CONTRAST 2 
 IMMUNO GLOBULINS IVIG 1 
  PROBIOTICS 1 
  ALBUMIN 1 
  TOTAL 6 
ANGIODEMA    
 ANTICONVULSANT PHENYTOIN 1 
 ANALGESIC ECOSPIRIN 1 
  TOTAL 2 
HYPONATREMIA    
 DIURETIC HYDROCHLORTHIAZIDE 1 
  TOTAL 1 
VERTIGO ANTICONVULSANT PHENYTOIN 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Frequency of serious ADRs along with drugs 
 
Figure 1. Serious ADRs due to Phenytoin 
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 Males  Females  
No of Patients enrolled (%)  27(45.30)  33(55.69)  
Mean Age ± Standard deviation (Years)  48.41 ±4.89 46.05 ±5.47 
 
Figure 2. Serious ADRs due to Paclitaxel 
Table 3. Gender Distribution of ADRs   
 
Figure 3. Causality assessment by WHO UMC scale   
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